Call
Funded by:
Contact persons
Dr. Petra Burgstaller
Co-Lead Venture Creation & MAxL
Christina Enke-Stolle
Co-Lead Venture Creation & MAxL
The next call for proposals will begin in the fall of 2026.
Participation
Applications may be submitted by Bavarian research teams working in
- universities
- university hospitals
- non-university public research institutions
Possible topic areas
- innovative drugs and therapies (including NCEs, biologicals, ATMPs, vaccines)
- innovative platform technologies in the field of prediction, prognosis or diagnostics in biotechnology (including approaches based on the application of digital technologies such as artificial intelligence and machine learning)
- innovative platform technologies for drug discovery and development (including approaches based on the application of digital technologies such as artificial intelligence and machine learning)
- innovative approaches in the field of digital health in biotechnology (especially if there is potential for reimbursement by the cost units under the Digital Health Care Act DVG).
The selection criteria
- sustainable business model and convincing spin-off potential
- high innovation potential and technical-scientific originality
- clear unique selling propositions in comparison to potential competitors
- positive IP situation, persuasive IP strategy
- dedicated and qualified team with a basic willingness to found a company
- significant technical-scientific risks
- attractive for seed financing or other funding at the end of the funding period